{ "item_title" : "Current Trends and Concerns in Infectious Diseases", "item_author" : [" I. W. Fong "], "item_description" : "Chapter 1: Prevention of HIV infection.Abstract.1.0 Introduction and background.1.1. General non-pharmacological measures.1.2. Prevention of perinatal HIV transmission.1.2.1. Breast-feeding and HIV transmission.1.3. Postexposure prophylaxis for cutaneous exposure.1.3.1. Nonhuman primate studies.1.3.2. Postexposure prophylaxis after percutaneous or occupational exposures.1.4. Sexual transmission of HIV and non-occupational needle exposure.1.4.1. Biology of sexual HIV transmission.1.5. Early ART for HIV infection as prevention..1.6. Postexposure prophylaxis after sexual exposure.1.7. Preexposure prevention of HIV.1.7.1. Topical microbicides for PrEP.1.7.2. Oral PrEP in MSM..1.7.3. Oral PrEP in heterosexuals and drug users.1.8. Prospects of future effective HIV vaccine.1.9. Viewpoints and future direction.Table 1.1. Risk of HIV transmission by various routes.Table 1.2. Indication for postexposure prophylaxis.Table 1.3. Preexposure preventative measures for HIV infection.References. Chapter 2. Immune Reconstitution inflammatory Syndrome and Paradoxical Reaction.Abstract.2.0. Introduction.2.1. Paradoxical reaction syndrome.2.2 Immunosuppressive IRIS.2.2.1. Transplant IRIS.2.2.2. Biological therapy IRIS.2.3. HIV IRIS, 2.3.1. Pathogenesis of HIV IRIS.2.4.0. Clinical types of HIV IRIS.2.4.1. HIV tuberculosis IRIS. 2.4.2. HIV-associated cryptococcal IRIS.2.4.3. HIV-associated PML IRIS.2.4.4. HIV CNS IRIS without opportunistic infection.2.4.5. HIV cytomegalovirus IRIS.2.4.6. HIV Kaposi sarcoma IRIS.2.4.7. Miscellaneous HIV IRIS. 2.4.8. Management of HIV IRIS.2.5. Discussion and future directions.Table 2.1. Paradoxical reaction syndromes: not related to immunosuppression.Table 2.2. Immunosuppressive IRIS.Table 2,3. HIV IRIS subtypes.References.Chapter 3: Issues in Community-acquired Pneumonia.Abstract.3.0. Introduction.3.1. Airway defenses and pathogenesis.3.2. Microbiology of community-acquired pneumonia.3.2.1. Comments on microbial etiology.3.3. Diagnosis of community-acquired pneumonia.3.4. Markers of prognosis3.4.1. Comments on prediction scores.3.5. Treatment of community-acquired pneumonia.3.5.1 Comments on treatment.3.6. Adjunctive therapy.3.6.1. Comments on adjunctive therapy.3.7. Prevention3.7.1. Comments on prevention.Table 3.1. CURB-65 score.Table 3.2. IDSA/ATS guidelines for ICU management.References. Chapter 4: Helicobacter pylori infection: when should it be treated?Abstract.4.0. Background.4.1. Transmission.4.2. Pathogenesis.4.3. Clinical diseases and associated mechanisms.4.4. Treatment of clinical diseases.4.4.1. Peptic ulcer disease.4.4.2. Dyspepsia.4.4.3. MALT lymphoma.4.4.4. Gastric cancer.4.4.5. Miscellaneous conditions.4.5. Treatment regimens.4.6. Prevention.4.7. Comments and future directions.Figure 4.1. Outline of the pathogenesis of H. pylori infection.Figure 4.2. Course and clinical diseases of H. pylori infection.Table 4.1. Diagnostic tests for H. pylori infection.Table 4.2. Indications for H. pylori treatment.Table 4.3. Main regimens for H. pylori infection.References.", "item_img_path" : "https://covers3.booksamillion.com/covers/bam/3/03/036/968/3030369684_b.jpg", "price_data" : { "retail_price" : "249.99", "online_price" : "249.99", "our_price" : "249.99", "club_price" : "249.99", "savings_pct" : "0", "savings_amt" : "0.00", "club_savings_pct" : "0", "club_savings_amt" : "0.00", "discount_pct" : "10", "store_price" : "" } }

Overview

Customers Also Bought

Details